Brussels/Belgium, 19 May 2006 – Results from ESPRIT (European/Australasian Stroke Prevention in Reversible Ischaemia Trial), published in The Lancet today, confirm that extended-release dipyridamole plus acetylsalicylic acid (ASA)?, marketed as Aggrenox® or Asasantin® Retard, is superior to acetyl salicylic acid (ASA) as an antithrombotic prevention treatment for stroke patients.1 The study showed a statistically significant 20 percent relative risk reduction of primary outcome events (nonfatal stroke, death from all vascular causes, nonfatal myocardial infarction, or major bleeding complication) in patients treated with extended-release dipyridamole plus ASA compared with patients treated with ASA alone.
